Nieva, Jorge http://orcid.org/0000-0003-1605-4719
Reckamp, Karen L.
Potter, Danielle
Taylor, Aliki
Sun, Ping
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 29 March 2022
First Online: 3 June 2022
Declarations
:
: The work was funded by AstraZeneca, the manufacturer of osimertinib.
: J. Nieva reports ownership of stock/shares for Cansera, Epic Sciences, and Quantgene and has received honoraria from AstraZeneca, Fujirebio, Genentech, Western Oncolytics, Takeda, and Amgen. J. Nieva has received research grants/funds from Genentech and Merck & Co. K. Reckamp received personal fees for consulting from Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Calithera, Euclises, Genentech, Guardant, Janssen, Lilly, Merck KGA, Precision Health, Seattle Genetics, Takeda, and Tesaro. K. Reckamp received (institution) research grants/funds from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno. D. Potter was an employee of AstraZeneca when this research was conducted. D. Potter joined ASCO and CancerLinQ after participating in this study. This study and related conclusions reflect the independent work of study authors and do not necessarily represent the views of ASCO or CancerLinQ. A. Taylor and P. Sun are employees of AstraZeneca and report ownership of stocks/shares. Medical writing support for the development of this article, under the direction of the authors, was provided by Preeyah Purang, BSc and Gemma White, MSc, of Ashfield MedComms UK, an Ashfield Health company, and was funded by AstraZeneca.
: Institutional review board approval was not sought as the CLQD database is a secondary source of data, consisting only of collected de-identified data; no patient-identifiable information was included in the analytical dataset.
: Patient consent was not required for this retrospective study as personal health information was not needed.
: Not applicable.
: Data underlying the findings described in this article may be obtained on request in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: Not applicable.
: Conceptualization: JN, KR, DP. Formal analysis: PS. Funding acquisition: AT. Methodology: JN, KR, AT, PS. Project administration: AT. Supervision: DP, AT. Validation: JN, AT, PS. Visualization: KR, PS. Writing, original draft preparation: JN, KR, AT. Writing, review, and editing: JN, KR, DP, AT.